Pharmacy Benefit Management

From Specialty Pharmacy News - The second FDA-approved biosimilar is set to hit the U.S. market by the end of this month. Inflectra (infliximab-dyyb) will launch at a 15% discount to the wholesale acquisition cost of Janssen Biotech, Inc.’s reference drug Remicade (infliximab), according to Pfizer Inc., which will market the biosimilar in the U.S. While that discount may not be as much as industry experts had expected, the drug still should offer some savings. Read more

From Drug Benefit News - As the abuse and misuse of opioids became a national health problem, some state legislators began taking steps to curb this, passing legislation to require insurers to cover FDA-validated abuse-deterrent opioids, as well as put limits on their cost-sharing approaches for members. And while such legislation seems to be having an impact on prescribing, these drugs come at a much higher cost than do opioids without FDA validation, but their… Read more

Pharmacy Benefit Management Blog

By Lauren Flynn Kelly - April 14, 2016
In the latest squabble between drugstores and PBMs, the National Community Pharmacists Association (NCPA) on April 1 issued a letter to CMS Deputy Director Cynthia Tudor asserting that Medicare Part D plans and PBMs are not complying with a federal requirement to use drug pricing standards that “...
By Angela Maas - March 30, 2016
As high drug prices continue to make headlines and draw congressional ire, hepatitis C drugs and “Mr. Wu-Tang” Martin Shkreli seem to be getting a reprieve as focus turns to the prostate cancer drug Xtandi. On March 28, 12 members of Congress sent a letter to HHS Sec. Sylvia Burwell and Francis...
By Lauren Flynn Kelly - March 4, 2016
Since the introduction of direct-acting antivirals that in clinical trials demonstrated higher sustained virologic response (SVR) rates in hepatitis C patients than ever before, we’ve seen figures on sales, treatment costs, adherence levels, etc. For example, Harvoni (ledipasvir and sofosbuvir) and...

It's quick and easy to sign up for FREE access to!

Why do I need to register?